Constrained Evolution of Human Immunodeficiency Virus Type 1 Protease during Sequential Therapy with Two Distinct Protease Inhibitors

Human immunodeficiency virus type 1 (HIV-1) variants that have developed protease (PR) inhibitor resistance most often display cross-resistance to several molecules within this class of antiretroviral agents. The clinical benefit of the switch to a second PR inhibitor in the presence of such resista...

ver descrição completa

Detalhes bibliográficos

Publicado no:	J Virol
Principais autores:	Dulioust, Anne, Paulous, Sylvie, Guillemot, Laurent, Delavalle, Anne-Marie, Boué, François, Clavel, François
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 1999
Assuntos:	Vaccines and Antiviral Agents
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC103902/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9847401/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/jvi.73.1.850-854.1999
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!